atamtinib

Atamtinib (HQ-001) is a potent and selective small molecule inhibitor of the BRAF V600E mutation, developed by Shanghai Huiqi Biomedical Technology. It is primarily designed for the treatment of advanced solid tumors, including melanoma, that harbor the BRAF V600E mutation. By selectively binding to the mutated BRAF kinase, atamtinib inhibits the constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which is a critical driver of tumor cell proliferation and survival in these cancers. The drug is currently being evaluated in Phase 1/2 clinical trials to determine its safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy as a targeted therapy.